Sutro Biopharma, Inc. (STRO) is a publicly traded Healthcare sector company. As of May 21, 2026, STRO trades at $30.52 with a market cap of $571.35M and a P/E ratio of -1.26. STRO moved -1.80% today. Year to date, STRO is +186.38%; over the trailing twelve months it is +246.00%. Its 52-week range spans $5.23 to $46.00. Analyst consensus is strong buy with an average price target of $47.50. Rallies surfaces STRO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Sutro Biopharma Plans IND Submissions for Two ADCs, Holds $202.6M Cash: Sutro Biopharma ended Q1 with $202.6 million in cash and raised $110.0 million through a common stock offering, extending its cash runway into Q2 2028. The company’s STRO-004 Phase 1 dose-escalation trial remains on track for initial safety, PK and early activity data in mid-2026.
| Metric | Value |
|---|---|
| Price | $30.52 |
| Market Cap | $571.35M |
| P/E Ratio | -1.26 |
| EPS | $-24.53 |
| Dividend Yield | 0.00% |
| 52-Week High | $46.00 |
| 52-Week Low | $5.23 |
| Volume | 120 |
| Avg Volume | 0 |
| Revenue (TTM) | $99.61M |
| Net Income | $-153.60M |
| Gross Margin | 0.00% |
9 analysts cover STRO: 0 strong buy, 9 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $47.50.